Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00898534 · ClinicalTrials.gov registry record · Phase 4
Effect of Immediate Hemoglobin A1c on Glycemic Control in Children With Type I Diabetes Mellitus
A Phase 4 study, sponsored by Boston Children's Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 234
- Enrollment target
NCT00898534 is a Phase 4 study that has completed, run by Boston Children's Hospital. The registered enrollment target is 234 participants.
The verdict
NCT00898534, a Phase 4 study, has completed, sponsored by Boston Children's Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 234 participants
- Enrollment target
Study Summary
Immediate feedback of hemoglobin A1c (A1c) results to adults with type 1 and 2 diabetes allows more appropriate care decisions at the clinic visit and may improve glycemic control. The investigators' objective is to determine whether immediate feedback of A1c results to children with type 1 diabetes will improve patient care and glycemic control.
Interventions
- DEVICE Bayer DCA2000+ Hemoglobin A1c analyzer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 234 participants |
| Start Date | 2003-11 |
| Est. Completion | 2006-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00898534
The ClinicalTrials.gov registry entry for NCT00898534 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 234 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bayer DCA2000+ Hemoglobin A1c analyzer is the first listed.
NCT00898534 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00898534 about?
NCT00898534 is a clinical study titled "Effect of Immediate Hemoglobin A1c on Glycemic Control in Children With Type I Diabetes Mellitus". Immediate feedback of hemoglobin A1c (A1c) results to adults with type 1 and 2 diabetes allows more appropriate care decisions at the clinic visit and may improve glycemic control. The investigators' objective is to determine whether immediate feedback of A1c results to children with type 1 diabetes...
What is the current status of trial NCT00898534?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 234 participants. The study started on 2003-11. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00898534?
The interventions under investigation include: Bayer DCA2000+ Hemoglobin A1c analyzer (DEVICE).
Who is sponsoring clinical trial NCT00898534?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.